CN101068536B - S1p受体激动剂的剂量方案 - Google Patents

S1p受体激动剂的剂量方案 Download PDF

Info

Publication number
CN101068536B
CN101068536B CN2005800409686A CN200580040968A CN101068536B CN 101068536 B CN101068536 B CN 101068536B CN 2005800409686 A CN2005800409686 A CN 2005800409686A CN 200580040968 A CN200580040968 A CN 200580040968A CN 101068536 B CN101068536 B CN 101068536B
Authority
CN
China
Prior art keywords
alkyl
agonist
substituted
group
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800409686A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068536A (zh
Inventor
J·M·科瓦里克
S·阿佩尔-丁厄曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101068536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101068536A publication Critical patent/CN101068536A/zh
Application granted granted Critical
Publication of CN101068536B publication Critical patent/CN101068536B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
CN2005800409686A 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案 Expired - Fee Related CN101068536B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
US60/631,483 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100846463A Division CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Publications (2)

Publication Number Publication Date
CN101068536A CN101068536A (zh) 2007-11-07
CN101068536B true CN101068536B (zh) 2012-12-05

Family

ID=36046868

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800409686A Expired - Fee Related CN101068536B (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案
CN2012100846463A Pending CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100846463A Pending CN102600472A (zh) 2004-11-29 2005-11-28 S1p受体激动剂的剂量方案

Country Status (21)

Country Link
US (3) US20090275553A1 (https=)
EP (3) EP2384749A1 (https=)
JP (4) JP2008521827A (https=)
KR (4) KR20070085465A (https=)
CN (2) CN101068536B (https=)
AU (1) AU2005309378B2 (https=)
BR (1) BRPI0518674A2 (https=)
CA (1) CA2589265A1 (https=)
ES (1) ES2495690T3 (https=)
IL (2) IL183134A0 (https=)
MA (1) MA29034B1 (https=)
MX (1) MX2007006373A (https=)
NO (2) NO20072401L (https=)
NZ (2) NZ590054A (https=)
PL (1) PL1819326T3 (https=)
PT (1) PT1819326E (https=)
RU (2) RU2478384C2 (https=)
SG (2) SG187468A1 (https=)
TN (1) TNSN07209A1 (https=)
WO (1) WO2006058316A1 (https=)
ZA (1) ZA200703328B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
ES2529724T3 (es) * 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CA2684953C (en) * 2007-05-04 2016-08-09 Novartis Ag Use of s1p receptor modulator
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
CA2724592A1 (en) * 2008-05-20 2009-11-26 Kyorin Pharmaceutical Co., Ltd. Agent for maintenance of induced remission
EP2695615A3 (en) 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
KR101618906B1 (ko) * 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
NZ598534A (en) 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
BR112012028248A2 (pt) * 2010-05-06 2016-08-02 Novartis Ag derivados de sulfeto de diarila, seu uso, e kit
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003099A1 (en) * 2001-06-08 2003-01-02 Philip Lake Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
CA2442178A1 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
EP1381358B1 (en) * 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
EP1575576A2 (en) * 2002-09-24 2005-09-21 Novartis AG Organic compounds
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003099A1 (en) * 2001-06-08 2003-01-02 Philip Lake Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
CN1524002A (zh) * 2001-06-08 2004-08-25 ��˹��ŵ�� 治疗或预防产胰岛素细胞的移植排斥反应
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Andrej Skerjanec et al.Systemic exposure and preliminary effeccacy of FTY720 in denovo renal transplant recipents.Am. J. Transplant2.2002,2380. *

Also Published As

Publication number Publication date
CN102600472A (zh) 2012-07-25
RU2007124327A (ru) 2009-01-10
WO2006058316A1 (en) 2006-06-01
PT1819326E (pt) 2014-09-25
JP2012107059A (ja) 2012-06-07
PL1819326T3 (pl) 2014-12-31
US20150087720A1 (en) 2015-03-26
SG158096A1 (en) 2010-01-29
US20090275553A1 (en) 2009-11-05
EP2359821A1 (en) 2011-08-24
KR20140095109A (ko) 2014-07-31
MX2007006373A (es) 2007-06-20
BRPI0518674A2 (pt) 2008-12-02
JP2013129664A (ja) 2013-07-04
RU2012141951A (ru) 2014-04-10
ES2495690T3 (es) 2014-09-17
MA29034B1 (fr) 2007-11-01
SG187468A1 (en) 2013-02-28
IL223502A0 (en) 2013-02-03
RU2478384C2 (ru) 2013-04-10
CN101068536A (zh) 2007-11-07
AU2005309378A1 (en) 2006-06-01
EP1819326A1 (en) 2007-08-22
CA2589265A1 (en) 2006-06-01
NO20121305L (no) 2007-06-22
EP1819326B1 (en) 2014-07-02
JP2015061883A (ja) 2015-04-02
IL183134A0 (en) 2008-04-13
JP2008521827A (ja) 2008-06-26
TNSN07209A1 (en) 2008-11-21
NZ590054A (en) 2012-07-27
NO20072401L (no) 2007-06-22
ZA200703328B (en) 2008-08-27
KR20070085465A (ko) 2007-08-27
AU2005309378B2 (en) 2010-02-11
KR20130041385A (ko) 2013-04-24
US20120071446A1 (en) 2012-03-22
EP2384749A1 (en) 2011-11-09
HK1109057A1 (en) 2008-05-30
KR20150028858A (ko) 2015-03-16
NZ554720A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CN101068536B (zh) S1p受体激动剂的剂量方案
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
JP6624616B2 (ja) ｓＧＣ刺激剤
CN101237852A (zh) 液体制剂
CN101791406B (zh) 1-磷酸-鞘氨醇(s1p)受体激动剂用于制备治疗脑变性性疾病的药物的应用
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
KR20180022661A (ko) 신경퇴행성 질환을 치료하는 방법
CN1406128A (zh) 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用
EA032028B1 (ru) СТИМУЛЯТОРЫ рГЦ
JP2010510214A (ja) Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法
KR20190094167A (ko) sGC 자극제를 사용한 CNS 질환의 치료
RU2006135927A (ru) Бифенильные соединения, полезные в качестве антагонистов мускариновых рецепторов
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
CN101466365A (zh) 增强认知功能的方法
KR20060017763A (ko) 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도
JP2008514718A (ja) 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US20260021078A1 (en) Compositions and methods for the treatment or prevention of pulmonary hypertension
RU2007128085A (ru) Соли четвертичного аммония в качестве антагонистов м3
WO1994025023A9 (en) Use of indole derivatives as 5ht1 antagonists
EP0808166A1 (fr) Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports
DE69911373T2 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
US6492387B2 (en) Isoindolyl and isoquinolinyl aroyl pyrrole compounds
KR20010099648A (ko) 신규 조성물
CN115427033B (zh) 用于治疗选自脓毒症、脓毒症休克、急性呼吸窘迫综合征(ards)或多器官功能障碍综合征(mods)的疾病的nk-1受体拮抗剂
JP2005097196A (ja) Ｎ型カルシウムチャンネル阻害剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121205

Termination date: 20141128

EXPY Termination of patent right or utility model